title: Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM.
abstract: Fibroblast growth factor 21 (FGF-21) has been identified as a potent metabolic regulator. Despite the importance of FGF-21 in the regulation of glucose, lipid and energy homeostasis, much less is known about the effect of common anti-diabetic treatment on the plasma levels of FGF-21. The aim of our study was to measure its plasma levels in patients with new-onset type 2 diabetes mellitus (nT2DM) and healthy subjects, and to assess the changes of its circulating levels after pharmacological interventions. One hundred and eleven patients with nT2DM, and 87 gender-, age- and body mass index (BMI)-matched normal glucose tolerance (NGT) controls participated in the study. The patients with nT2DM were treated with mitiglinide for 16 weeks. Biochemical parameters, plasma FGF-21 and insulin levels were measured by commercial ELISA or RIA kits pre- and post-treatment with mitiglinide. Fasting plasma FGF-21 levels were higher in the nT2DM group than in controls (3.21 ± 1.37 vs. 1.52 ± 0.36 μg/L, P<0.01). In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after mitiglinide treatment for 16 weeks (3.21 ± 1.37 vs. 2.79 ± 1.14μg/L, P<0.05), accompanied by significant amelioration of glucose metabolism. Our study showed that mitiglinide treatment decreased plasma FGF-21 levels, and this decrease might be associated with the amelioration of glucose metabolism.
authors: The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of Education, Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, 400016 Chongqing, China.
authors: Bo
authors: B
authors: Wang
authors: Gangyi
authors: G
authors: Yang
authors: Mengliu
authors: M
authors: Yang
authors: Yong
authors: Y
authors: Liao
authors: Zhiyong
authors: Z
authors: Li
authors: Guenther
authors: G
authors: Boden
authors: Ling
authors: L
authors: Li
mesh_terms: D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005215:Fasting / Q000097:blood; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D054833:Isoindoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D054833:Isoindoles; C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors; C087255:mitiglinide